Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods

Patent metadata

Field	Value
Publication number	US-10588977-B2
Application number	US-201816186866-A
Country	US
Kind code	B2
Filing date	Nov 12, 2018
Priority date	May 16, 2007
Publication date	Mar 17, 2020
Grant date	Mar 17, 2020

Abstract

The invention provides a composition containing hyaluronic acid (HA) or a pharmaceutically-acceptable salt thereof preserved with a cationic preservative and related methods. In one embodiment, the pharmaceutically-acceptable salt is sodium hyaluronate. In another embodiment, the cationic preservative includes benzalkonium chloride (BAK).

First claim

What is claimed is:

1. A method for preparing a preserved hyaluronic acid composition, the method comprising:
dissolving a cationic preservative in a first quantity of a solvent;
dissolving a quantity of hyaluronic acid (HA) or physiologically-acceptable salt thereof in a second quantity of the solvent; and
adding the dissolved HA or physiologically-acceptable salt thereof to the dissolved cationic preservative,
wherein precipitation of the cationic preservative and the HA or physiologically-acceptable salt thereof is substantially prevented by dissolving each in the first and second quantities of solvent before they are combined, wherein the cationic preservative is selected from salts of alexidine, alexidine-free base or mixtures thereof and further wherein the first quantity of the solvent and the second quantity of the solvent are combined at a ratio, the ratio of the first quantity of the solvent to the second quantity of the solvent being between about 1.8:1 and about 2.2:1.

2. A method for preparing a preserved hyaluronic acid composition, the method comprising:
dissolving a cationic preservative in a first quantity of a solvent;
dissolving a quantity of hyaluronic acid (HA) or physiologically-acceptable salt thereof in a second quantity of the solvent; and
adding the dissolved HA or physiologically-acceptable salt thereof to the dissolved cationic preservative,
wherein precipitation of the cationic preservative and the HA or physiologically-acceptable salt thereof is substantially prevented by dissolving each in the first and second quantities of solvent before they are combined, wherein the cationic preservative is selected from salts of alexidine, alexidine-free base or mixtures thereof and further wherein the first quantity of the solvent and the second quantity of the solvent are combined at a ratio, the ratio of the first quantity of the solvent to the second quantity of the solvent being about 2:1.

Assignees

• Johnson & Johnson Consumer Inc

Inventors

• Doshi Uday
• Holeva Kenneth T

Classifications

• C07C279/28

  having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides · CPC title

• A61K47/18

  Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids · CPC title

• A61K31/155

  Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2) · CPC title

• A61K31/728

  Hyaluronic acid · CPC title

• A61K9/0048

  Eye, e.g. artificial tears · CPC title